Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal DoxorubicinPLDan Dynamic Randomized, Positive Control, Open, Multicenter Clinical Study
Latest Information Update: 02 Jul 2023
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Early breast cancer
- Focus Adverse reactions
Most Recent Events
- 02 Jul 2023 New trial record
- 06 Jun 2023 Results assessing safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin presented at the 59th Annual Meeting of the American Society of Clinical Oncology